Lymphocyte collection for cellular therapy
DOI:
https://doi.org/10.46765/2675-374X.2025v7n1e330Keywords:
Leukapheresis, CAR-T cell, DLI , Lymphocyte collectionAbstract
Introduction: Leukapheresis is the starting point of cellular therapies such as chimeric antigen receptor T cells (CAR-T cells) and donor lymphocyte infusion. Methods: After a review of the literature, we provided guidance on how to evaluate candidates for leukapheresis and how to optimize the safety and efficacy of the procedure. Results: Clinical and laboratory assessment is warranted prior to leukapheresis. T cell fitness is impacted by previous treatments, ageing, and tumor burden. The most common adverse reaction is hypocalcemia. Conclusion: Leukapheresis is a safe and effective procedure. Technical and clinical aspects must be observed to preserve T cell fitness, ensure manufacturing success, and guarantee patient safety and clinical efficacy. The current challenge is to standardize guidelines for pre-leukapheresis requirements and collection yield improvement.
References
1. Neelapu SS, Jacobson CA, Ghobadi A, Locke FL, Miklos DB, Lekakis LJ, et al. Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma. Blood. 2023;141(19):2307-2315. https://doi.org/10.1182/blood.2022018893 DOI: https://doi.org/10.1182/blood.2022018893
2. San-Miguel J, Dhakal B, Yong K, Mateos MV, Landgren O, Lentzsch S, et al. Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. N Engl J Med. 2023;389(4):335-347. https://doi.org/10.1056/NEJMoa2303379 DOI: https://doi.org/10.1056/NEJMoa2303379
3. Laetsch TW, Maude SL, Rives S, Hiramatsu H, Bader P, Baruchel A, et al. Three-year update of tisagenlecleucel in pediatric and young adult patients with relapsed/refractory acute lymphoblastic leukemia in the ELIANA trial. J Clin Oncol. 2023;41(9):1664-1669. https://doi.org/10.1200/JCO.22.00642 DOI: https://doi.org/10.1200/JCO.22.00642
4. Pagliuca S, Schmid C, Santoro N, Potter V, Onida F, Snowden JA, et al. Donor lymphocyte infusion after allogeneic haematopoietic cell transplantation for haematological malignancies: basic considerations and best practice recommendations from the EBMT. Lancet Haematol. 2024;11(6):e448-e458. https://doi.org/10.1016/S2352-3026(24)00098-X DOI: https://doi.org/10.1016/S2352-3026(24)00098-X
5. Wada F, Jo T, Arai Y, Nishida T, Saito S, Nakagawa M, et al. T-cell counts in peripheral blood at leukapheresis predict responses to subsequent CAR-T cell therapy. Sci Rep. 2022;12(1):18696. https://doi.org/10.1038/s41598-022-23589-9 DOI: https://doi.org/10.1038/s41598-022-23589-9
6. Mehta PH, Fiorenza S, Koldej RM, Tognela A, Kueberuwa G, Mian A, et al. T cell fitness and autologous CAR T cell therapy in haematologic malignancy. Front Immunol. 2021;12:780442. https://doi.org/10.3389/fimmu.2021.780442 DOI: https://doi.org/10.3389/fimmu.2021.780442
7. Costa LJ, Banerjee R, Mian H, Richardson PG, Rodriguez C, Kumar SK, et al. International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myeloma. Leukemia. 2025;39(3):543-554. https://doi.org/10.1038/s41375-024-02482-6 DOI: https://doi.org/10.1038/s41375-024-02482-6
8. Qayed M, McGuirk JP, Myers GD, Bachanova V, Bishop MR, Turtle CJ, et al. Leukapheresis guidance and best practices for optimal chimeric antigen receptor T-cell manufacturing. Cytotherapy. 2022;24(9):869-878. https://doi.org/10.1016/j.jcyt.2022.05.003 DOI: https://doi.org/10.1016/j.jcyt.2022.05.003
9. Hayden PJ, Roddie C, Bader P, Basak GW, Bonig H, Bonini C, et al. Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA). Ann Oncol. 2022;33(3):259-275. https://doi.org/10.1016/j.annonc.2021.12.003 DOI: https://doi.org/10.1016/j.annonc.2021.12.003
10. Worel N, Holbro A, Vrielink H, Schmetzer HM, Bosman P, Hirscher V, et al. A guide to the collection of T cells by apheresis for ATMP manufacturing – recommendations of the GoCART coalition apheresis working group. Bone Marrow Transplant. 2023;58(7):742-748. https://doi.org/10.1038/s41409-023-01957-x DOI: https://doi.org/10.1038/s41409-023-01957-x
11. Thibodeaux SR, Aqui NA, Park YA, Tang Y, Lee DW, Bishop MR, et al. Lack of defined apheresis collection criteria in publicly available CAR-T cell clinical trial descriptions: comprehensive review of over 600 studies. J Clin Apher. 2022;37(3):223-236. https://doi.org/10.1002/jca.21964 DOI: https://doi.org/10.1002/jca.21964
12. Tuazon SA, Li A, Gooley T, Riddell SR, Maloney DG, Turtle CJ, et al. Factors affecting lymphocyte collection efficiency for the manufacture of chimeric antigen receptor T cells in adults with B-cell malignancies. Transfusion. 2019;59(5):1773-1780. https://doi.org/10.1111/trf.15178 DOI: https://doi.org/10.1111/trf.15178
13. Piñeyroa JA, Cid J, Lozano M. Get off on the right foot: how to plan an efficient leukocytapheresis to collect T cells for CAR T-cell manufacturing. Transfus Med Hemother. 2022;50(2):98-104. https://doi.org/10.1159/000528331 DOI: https://doi.org/10.1159/000528331
14. O’Reilly MA, Malhi A, Cheok KPL, Hwang WY, Lim SH, Ritchie DS, et al. A novel predictive algorithm to personalize autologous T-cell harvest for chimeric antigen receptor T-cell manufacture. Cytotherapy. 2023;25(3):323-329. https://doi.org/10.1016/j.jcyt.2022.10.012 DOI: https://doi.org/10.1016/j.jcyt.2022.10.012
15. Bolan CD, Cecco SA, Wesley RA, Hillyer CD, Corbin TM, Swerdlow PS, et al. Controlled study of citrate effects and response to i.v. calcium administration during allogeneic peripheral blood progenitor cell donation. Transfusion. 2002;42(7):935-946. https://doi.org/10.1046/j.1537-2995.2002.00151.x DOI: https://doi.org/10.1046/j.1537-2995.2002.00151.x
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Sérgio Luiz Arruda Parente Filho, Suzanna Tavares Barbosa, Naliele Cristina Maia de Castro, Araci Sakashita
This work is licensed under a Creative Commons Attribution 4.0 International License.
